SEARCH:   Advanced

Blood, 15 September 2004, Vol. 104, No. 6, pp. 1624-1630. Prepublished online as a Blood First Edition Paper on June 3, 2004; DOI 10.1182/blood-2003-12-4428. This Article Full Text (PDF) All Versions of this Article: 2003-12-4428v1 104/6/1624    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Thomas, D. A Articles by Kantarjian, H. Search for Related Content PubMed PubMed Citation Articles by Thomas, D. A Articles by Kantarjian, H. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 12, 2004 Accepted May 7, 2004 Outcome with the Hyper-CVAD Regimens in Lymphoblastic Lymphoma Deborah A Thomas*, Susan M O'Brien, Jorge Cortes, Francis J Giles, Stefan Faderl, Srdan Verstovsek, Alessandra Ferrajoli, Charles Koller, Miloslav Beran, Sherry Pierce, Chul S Ha, Fernando Cabanillas, Michael J Keating, and Hagop Kantarjian Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA Department of Lymphoma, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA * Corresponding author; email: debthomas{at}mdanderson.org. Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL). We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD or modified hyper-CVAD used for ALL at our institution. Induction-consolidation was administered with eight or nine alternating cycles of chemotherapy over 5-6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy. Consolidative radiation therapy was given to patients with mediastinal disease at presentation. No consolidation with autologous or allogeneic stem cell transplant was performed. At diagnosis, 80% were T-cell immunophenotype, 70% were stage III-IV, 70% had mediastinal involvement, and 9% had CNS disease. Thirty patients (91%) achieved complete remission, and 3 (9%) achieved partial response. Ten patients (30%) relapsed or progressed within a median of 13 months. Estimates for 3-year progression-free and overall survival for the 33 patients were 66% and 70%, respectively. Estimates for the patients with known T-cell immunophenotype were 62% and 67%, respectively. No parameters (e.g., age, stage, serum lactate dehydrogenase [LDH], b2 microglobulin) appeared to influence outcome except for CNS disease at presentation. Modification of the hyper-CVAD regimen with anthracycline intensification did not improve outcome. Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. A. Thomas, H. Kantarjian, S. Faderl, W. G. Wierda, A. Ferrajoli, J. A. Burger, J. Cortes, C. A. Koller, G. Borthakur, Z. Estrov, et al. Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL). Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 1931 - 1931. [Abstract] M. Hunault, M. Truchan-Graczyk, D. Caillot, J.-L. Harousseau, S. Bologna, C. Himberlin, D. Guyotat, C. Berthou, P. Casassus, L. Baranger, et al. Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial Haematologica, December 1, 2007; 92(12): 1623 - 1630. [Abstract] [Full Text] [PDF] E. Jabbour, S. O'Brien, H. Kantarjian, G. Garcia-Manero, A. Ferrajoli, F. Ravandi, M. Cabanillas, and D. A. Thomas Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia Blood, April 15, 2007; 109(8): 3214 - 3218. [Abstract] [Full Text] [PDF] K. Song, M. Barnett, R. Gascoyne, M Chhanabhai, D. Forrest, D. Hogge, J. Lavoie, S. Nantel, T. Nevill, J. Shepherd, et al. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes Ann. Onc., March 1, 2007; 18(3): 535 - 540. [Abstract] [Full Text] [PDF] C. B. Greenberg, P. A. Boria, A. Borgatti-Jeffreys, R. E. Raskin, and M. D. Lucroy Phase II Clinical Trial of Combination Chemotherapy With Dexamethasone for Lymphoma in Dogs J. Am. Anim. Hosp. Assoc., January 1, 2007; 43(1): 27 - 32. [Abstract] [Full Text] [PDF] J. T. Sandlund Should Adolescents with NHL Be Treated as Old Children or Young Adults? Hematology, January 1, 2007; 2007(1): 297 - 303. [Abstract] [Full Text] [PDF] D. A. Thomas, H. M. Kantarjian, J. L. Jorgensen, S. Faderl, J. Cortes, F. Giles, G. Garcia-Manero, W. Wierda, A. Ferrajoli, F. Ravandi-Kashani, et al. Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 1861 - 1861. [Abstract] [PDF] D. J. DeAngelo The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Hematology, January 1, 2005; 2005(1): 123 - 130. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020